DOJ Sues NewYork-Presbyterian: Antitrust Lawsuit Explained

In late March 2026, the U.S. Department of Justice filed a civil antitrust lawsuit against NewYork-Presbyterian Hospital — the largest and most powerful hospital system in New York City, owning and operating eight hospitals and many outpatient facilities in the New York City area. The complaint, filed in the U.S. District Court for the Southern District of New York, charges the system with violating Section 1 of the Sherman Act through a set of contracting practices that, the government argues, systematically eliminate price competition and deny millions of New Yorkers access to more affordable health insurance options. The case is not just about one hospital system. It is a signal — arguably the clearest one in years — that federal antitrust enforcement in healthcare is entering a more aggressive phase.

What NewYork-Presbyterian Is Accused Of

The core allegations center on how NewYork-Presbyterian structures its contracts with health insurers. As alleged in the complaint, NewYork-Presbyterian imposes plan restrictions in its contracts with payors that prevent payors from offering plans that do not include NewYork-Presbyterian or do not feature NewYork-Presbyterian in the most favored tier of the plan. NewYork-Presbyterian even forbids payors from offering lower copays when patients chose to receive care at NewYork-Presbyterian’s — often lower priced — rivals.

These are not minor administrative preferences. They represent a comprehensive contractual architecture designed to make it financially irrational for insurers to exclude or disadvantage NewYork-Presbyterian in their network designs — regardless of what competing hospitals charge or how their quality compares.

The DOJ alleges the health system uses its powerful market share in New York City to force insurers into “all-or-nothing” contracts. Insurers must include all of NewYork-Presbyterian’s facilities in nearly every network or forgo including them at all. The practical effect is that insurers who want access to NewYork-Presbyterian’s brand and patient base — which, given the system’s dominance, is nearly all of them — must accept terms that foreclose the development of budget-conscious, narrow-network, or tiered products.

By forcing insurers to include NewYork-Presbyterian in all plan networks, NewYork-Presbyterian degrades plans’ “steering” features, which insurers design to nudge patients to less expensive providers. As a result, insurers can’t design cheaper plans and NewYork-Presbyterian effectively doesn’t have to compete with other hospitals on prices.

Market Power as the Foundation

The DOJ’s theory of harm rests squarely on NewYork-Presbyterian’s market position. In 2024, the nonprofit made up more than 30% of the inpatient general acute care discharges in Manhattan and more than 25% in the four boroughs of Bronx, Brooklyn, Manhattan and Queens. The system includes Columbia University Medical Center and Weill Cornell Medical Center — two of the most recognized academic medical brands in the country.

The government describes NewYork-Presbyterian as having “substantially higher prices… even though its major competitors offer similarly high-quality healthcare,” naming NYU Langone, Mount Sinai, and Northwell as rivals. That pricing premium, the DOJ argues, is not earned through superior outcomes — it is maintained through contractual barriers that prevent the market from functioning. The DOJ alleges that the hospital’s “anticompetitive conduct” insulates it from price competition, allowing it to maintain its artificially high prices for medical care and health care services.

The Hospital’s Response

NewYork-Presbyterian has not accepted the government’s framing. The hospital called the claims meritless and said it had been cooperating with the Department’s inquiries and had begun what it thought were productive discussions with the Department’s leadership. NewYork-Presbyterian said it complies fully with all applicable federal and state laws and regulations.

The system also pushed back on the underlying power narrative: “In our contract negotiations with insurers, we seek to maximize access to the highest quality of care. Insurance companies hold the market power and use it to restrict patient choice,” NewYork-Presbyterian said. This counter-framing — positioning the hospital as the party protecting patient access rather than restricting it — is a predictable defense strategy, but it faces a difficult factual environment given the system’s documented market share and pricing premium.

A Pattern, Not an Isolated Case

The NewYork-Presbyterian lawsuit does not exist in a vacuum. The case comes just five weeks after the Justice Department filed a similar lawsuit against OhioHealth, which also accused the health system of using its market power to ink anticompetitive contracts with insurers, requiring payers to include all of its hospitals in their networks if they wanted access to any of them.

The enforcement pattern goes back further. In November 2018, the Antitrust Division settled a two-and-a-half year lawsuit against Atrium Health, a North Carolina hospital system formerly known as the Carolinas HealthCare System, enjoining Atrium’s anti-steering provisions against health plans. The DOJ had alleged that Atrium used its market power to insist on contract provisions with payors that limited or prohibited steering by the payors to lower-cost providers. Atrium settled without admitting wrongdoing and without paying fines, but the structural remedy — stripping anti-steering language from contracts — was a meaningful precedent.

What distinguishes the current moment is the explicit framing of these cases as a coordinated policy priority. The DOJ’s Thursday statement referenced the OhioHealth litigation and said both cases were brought in accordance with the administration’s focus on healthcare market competition and consumers’ affordable access. “Millions of New Yorkers pay more for healthcare because of these anticompetitive practices,” Attorney General Pamela Bondi said.

What the Contracting Practices Actually Do to the Market

To understand why these provisions matter beyond the legal arguments, it helps to trace how they affect the actual insurance market. Insurers design tiered and narrow network products precisely because price differentiation creates competition among providers. When a hospital can contractually mandate that it always occupy the top tier — and that patients face no financial incentive to go elsewhere — the mechanism that drives price competition stops working.

In a tiered network, the insurer separates providers into distinct tiers based on cost and quality and assigns corresponding copay amounts for each tier. A low-cost and high-quality provider is considered better value that would provide savings for both the insurer and the patient. Anti-tiering clauses eliminate that pricing signal entirely for whichever provider holds them.

Because many of the most innovative healthcare plans in the country today are based on steering to more efficient providers, Atrium’s steering restrictions had also curbed the introduction of such plans and reduced choices for Charlotte-area consumers — and the same logic applies in New York. The plans that exist in other U.S. markets but are unavailable in New York City represent a concrete, measurable cost to employers and workers.

What Could Happen Next

If the government proves its claims, judges could order NewYork-Presbyterian to stop enforcing the disputed contract terms and may award damages to harmed plans and employers, a remedy that could loosen the system’s grip on commercial insurance networks. Past enforcement suggests courts are willing to enjoin anti-steering clauses and require structural changes, although these cases can drag on for years and often turn on how the market is defined and whether there is clear evidence of consumer harm.

The most likely near-term outcome, based on the Atrium precedent, is a negotiated settlement in which NewYork-Presbyterian agrees to strip the challenged provisions from its contracts without admitting liability. That would be a meaningful win for the government — and for employers and insurers who have been unable to offer lower-cost products in the New York City market. But it would not, by itself, guarantee that premiums fall or that new plan designs emerge quickly. Markets move slowly, and insurers will need time to renegotiate contracts and build new products even after the legal constraint is removed.

Legal analysts told reporters that the NewYork-Presbyterian case will be an early test of how aggressively the Antitrust Division will go after vertical contracting practices in health care. Whether the DOJ litigates this to a verdict or settles, the message to large health systems is already in the record: the contracting toolkit that dominant hospitals have used for decades to insulate themselves from price competition is now squarely in federal enforcement crosshairs.

For the healthcare industry broadly — and for providers, payers, employers, and compliance teams specifically — the lesson is straightforward. Market power in healthcare does not confer unlimited contractual latitude. And in 2026, the federal government appears prepared to act on that principle at scale.

Sources